SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 20-F/A - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]: [Amend]
SEC Accession No. 0001493152-23-030148
Filing Date
2023-08-25
Accepted
2023-08-25 11:33:25
Documents
15
Period of Report
2023-03-31

Document Format Files

Seq Description Document Type Size
1 form20fa.htm   iXBRL 20-F/A 161579
2 ex12-1.htm EX-12.1 18617
3 ex12-2.htm EX-12.2 18461
  Complete submission text file 0001493152-23-030148.txt   474736

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE okyo-20230331.xsd EX-101.SCH 2915
5 XBRL DEFINITION FILE okyo-20230331_def.xml EX-101.DEF 27625
6 XBRL LABEL FILE okyo-20230331_lab.xml EX-101.LAB 37944
7 XBRL PRESENTATION FILE okyo-20230331_pre.xml EX-101.PRE 26271
9 EXTRACTED XBRL INSTANCE DOCUMENT form20fa_htm.xml XML 7267
Mailing Address 55 PARK LANE LONDON X0 W1K 1NA
Business Address 55 PARK LANE LONDON X0 W1K 1NA 44 (0) 207 495 2379
OKYO Pharma Ltd (Filer) CIK: 0001849296 (see all company filings)

IRS No.: 000000000
Type: 20-F/A | Act: 34 | File No.: 001-41386 | Film No.: 231204283
SIC: 2836 Biological Products, (No Diagnostic Substances)